BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 8613475)

  • 21. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
    Jo Y; Yeon J; Kim HJ; Lee ST
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat shock suppresses membrane type 1-matrix metalloproteinase production and progelatinase A activation in human fibrosarcoma HT-1080 cells and thereby inhibits cellular invasion.
    Sato T; Sawaji Y; Matsui N; Sato H; Seiki M; Mori Y; Ito A
    Biochem Biophys Res Commun; 1999 Nov; 265(1):189-93. PubMed ID: 10548512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
    Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
    Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
    de Bart AC; Quax PH; Löwik CW; Verheijen JH
    J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells.
    Tyagi SC; Lewis K; Pikes D; Marcello A; Mujumdar VS; Smiley LM; Moore CK
    J Cell Physiol; 1998 Aug; 176(2):374-82. PubMed ID: 9648925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
    Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
    Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase.
    Kinoshita T; Sato H; Takino T; Itoh M; Akizawa T; Seiki M
    Cancer Res; 1996 Jun; 56(11):2535-8. PubMed ID: 8653693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
    Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
    Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence quenching studies of matrix metalloproteinases (MMPs): evidence for structural rearrangement of the proMMP-2/TIMP-2 complex upon mercurial activation.
    Stack MS; Itoh Y; Young TN; Nagase H
    Arch Biochem Biophys; 1996 Sep; 333(1):163-9. PubMed ID: 8806767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase.
    Foda HD; George S; Conner C; Drews M; Tompkins DC; Zucker S
    Lab Invest; 1996 Feb; 74(2):538-45. PubMed ID: 8780171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T; Okada Y; Nakanuma Y
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
    Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
    J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
    Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
    J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
    Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
    Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
    Montgomery AM; De Clerck YA; Langley KE; Reisfeld RA; Mueller BM
    Cancer Res; 1993 Feb; 53(3):693-700. PubMed ID: 8425205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
    Fridman R; Toth M; Peña D; Mobashery S
    Cancer Res; 1995 Jun; 55(12):2548-55. PubMed ID: 7780967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells.
    Lewalle JM; Munaut C; Pichot B; Cataldo D; Baramova E; Foidart JM
    J Cell Physiol; 1995 Dec; 165(3):475-83. PubMed ID: 7593226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.